These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17461857)

  • 61. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
    Saag M; Goodrich J; Fätkenheuer G; Clotet B; Clumeck N; Sullivan J; Westby M; van der Ryst E; Mayer H;
    J Infect Dis; 2009 Jun; 199(11):1638-47. PubMed ID: 19432546
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Plasma human immunodeficiency virus (HIV) type 1 RNA load in men and women with advanced HIV-1 disease.
    Kalish LA; Collier AC; Flanigan TP; Kumar PN
    J Infect Dis; 2000 Aug; 182(2):603-6. PubMed ID: 10915096
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDS.
    Brites C; Gilbert MJ; Pedral-Sampaio D; Bahia F; Pedroso C; Alcantara AP; Sasaki MD; Matos J; Renjifo B; Essex M; Whitmore JB; Agosti JM; Badaro R
    J Infect Dis; 2000 Nov; 182(5):1531-5. PubMed ID: 11023477
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection.
    Flandre P; Chappey C; Marcelin AG; Ryan K; Maa JF; Bates M; Seekins D; Bernard MC; Calvez V; Molina JM
    J Infect Dis; 2007 Feb; 195(3):392-8. PubMed ID: 17205478
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations.
    Blanco JL; Biglia A; De Lazzari E; Mallolas J; Martinez E; Pumarola T; Larrousse M; Milinkovic A; León A; Lonca M; Laguno M; Gatell JM
    AIDS; 2006 Sep; 20(14):1891-2. PubMed ID: 16954732
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
    Akil B; Blick G; Hagins DP; Ramgopal MN; Richmond GJ; Samuel RM; Givens N; Vavro C; Song IH; Wynne B; Ait-Khaled M;
    Antivir Ther; 2015; 20(3):343-8. PubMed ID: 25321146
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection.
    Youle M; Osio M;
    HIV Med; 2007 May; 8(4):241-50. PubMed ID: 17461852
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Medical care for HIV infection in France in 2005, the NADIS cohort study on 7416 patients].
    Poizot-Martin I; Pugliese P; Enel P; Cuzin L; Billaud E; Duvivier C; Yazdanpanah Y;
    Med Mal Infect; 2006 Sep; 36(9):454-9. PubMed ID: 17030485
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: the INNOVE study.
    Morand-Joubert L; Ghosn J; Delaugerre C; Giffo B; Solas C; Samri A; Pinta A; Triglia A; Raffi F;
    J Med Virol; 2012 Nov; 84(11):1710-8. PubMed ID: 22997073
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
    Min S; Sloan L; DeJesus E; Hawkins T; McCurdy L; Song I; Stroder R; Chen S; Underwood M; Fujiwara T; Piscitelli S; Lalezari J
    AIDS; 2011 Sep; 25(14):1737-45. PubMed ID: 21716073
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
    Cotte L; Dellamonica P; Raffi F; Yazdanpanah Y; Molina JM; Boué F; Urata Y; Chan HP; Zhu L; Chang I; Bertz R; Hanna GJ; Grasela DM; Hwang C
    J Acquir Immune Defic Syndr; 2013 Jul; 63(3):346-54. PubMed ID: 23771104
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
    Jacobson JM; Saag MS; Thompson MA; Fischl MA; Liporace R; Reichman RC; Redfield RR; Fichtenbaum CJ; Zingman BS; Patel MC; Murga JD; Pemrick SM; D'Ambrosio P; Michael M; Kroger H; Ly H; Rotshteyn Y; Buice R; Morris SA; Stavola JJ; Maddon PJ; Kremer AB; Olson WC
    J Infect Dis; 2008 Nov; 198(9):1345-52. PubMed ID: 18771406
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial.
    Kemper CA; Haubrich R; Frank I; Dubin G; Buscarino C; McCutchan JA; Deresinski SC;
    J Infect Dis; 2003 Apr; 187(8):1327-31. PubMed ID: 12696015
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578).
    Wagner GJ; Kanouse DE; Golinelli D; Miller LG; Daar ES; Witt MD; Diamond C; Tilles JG; Kemper CA; Larsen R; Goicoechea M; Haubrich RH
    AIDS; 2006 Jun; 20(9):1295-302. PubMed ID: 16816559
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study.
    Reesink HW; Zeuzem S; Weegink CJ; Forestier N; van Vliet A; van de Wetering de Rooij J; McNair L; Purdy S; Kauffman R; Alam J; Jansen PL
    Gastroenterology; 2006 Oct; 131(4):997-1002. PubMed ID: 17030169
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial.
    Boffito M; Fox J; Bowman C; Fisher M; Orkin C; Wilkins E; Jackson A; Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
    Vaccine; 2013 Nov; 31(48):5680-6. PubMed ID: 24120550
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.
    Kinloch-de Loes S; Hoen B; Smith DE; Autran B; Lampe FC; Phillips AN; Goh LE; Andersson J; Tsoukas C; Sonnerborg A; Tambussi G; Girard PM; Bloch M; Battegay M; Carter N; El Habib R; Theofan G; Cooper DA; Perrin L;
    J Infect Dis; 2005 Aug; 192(4):607-17. PubMed ID: 16028129
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Modelling the association between adherence and viral load in HIV-infected patients.
    Vrijens B; Goetghebeur E; de Klerk E; Rode R; Mayer S; Urquhart J
    Stat Med; 2005 Sep; 24(17):2719-31. PubMed ID: 16118813
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.
    Moyle G; Boffito M; Stoehr A; Rieger A; Shen Z; Manhard K; Sheedy B; Hingorani V; Raney A; Nguyen M; Nguyen T; Ong V; Yeh LT; Quart B
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3170-8. PubMed ID: 20498326
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267.
    Wohl DA; Aweeka FT; Schmitz J; Pomerantz R; Cherng DW; Spritzler J; Fox L; Simpson D; Bell D; Holohan MK; Thomas S; Robinson W; Kaplan G; Teppler H;
    J Infect Dis; 2002 May; 185(9):1359-63. PubMed ID: 12001058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.